Subscribe
Subscribe

Sanofi acquires Ablynx for €3.9 billion

Sanofi and Ablynx entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of €45 in cash, which represents an aggregate equity value of approximately €3.9 billion. The transaction was unanimously approved by both the Sanofi and Ablynx Boards of Directors.

Nominations open for Dr. Paul Janssen Award

Have you ever heard from the Dr. Paul Janssen award? It's an acknowledgement for biomedical research almost as important as a Nobel Prize. A trophy sculpture, along with $200,000 cash, will go to the most passionate and creative scientist or team, whose work has made the strongest impact on human health.

Rewind Therapeutics secures funding for Multiple Sclerosis research

reMYND brings in Novo Nordisk to develop diabetes therapy

Celyad: CAR-T cells with natural killer skills fight cancer

Synthetic biology – revolutionary technology in search of a better name

Engineering compounds to protect crops from drought

Vaccinating against cancer with dendritic cells

Founded as a spin-off from the French Blood Bank, PDC*line Pharma is focused on developing immunotherapeutic vaccines. These vaccines contain their proprietary and unique plasmacytoid dendritic cell (PDC) line, whose remarkable characteristics make it excellently suited for immunotherapy. By boosting the immune system with their vaccine in combination with checkpoint inhibitors, PDC*line Pharma aims to help the currently large group of non-responders to immunotherapy.

Reveal every detail of your mAbs with micro-Chips

First to file? How to handle post-experimental data

Diagnosed with lung cancer

Tackling untreatable cancers in children

ImmunXperts: your partner for in vitro assays in cancer immunotherapy

Although immunotherapy in cancer is booming, it isn’t by any measure an easy field to navigate. Many oncology ventures willing to explore this new terrain [...]

Personalized healthcare, a long-awaited revolution

Walloon radio-isotope technology in the fight against cancer